The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The U.S. Food and Drug Administration on Monday approved Biocon unit's biosimilar to Regeneron Pharmaceuticals' blockbuster ...
Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the ...
The European Commission approved Bristol Myers Squibb’s Opdivo combination therapy for urothelial cancer based on Phase III ...
Analyst Salim Syed from Mizuho Securities maintained a Hold rating on Amgen (AMGN – Research Report) and keeping the price target at ...
Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma ...
Lung Cancer is a complex and devastating disease with over 200,000 new cases in 2024 alone. Small Cell Lung Cancer, or SCLC, is one of the most aggressive cancers out there, ...
Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new ...
US FDA grants Breakthrough Device Designation to Roche’s blood test measuring Lp(a), a key marker for hereditary cardiovascular risk: Basel Thursday, May 23, 2024, 13:00 Hrs [IS ...